AU2002332391A1 - Human secreted proteins - Google Patents

Human secreted proteins

Info

Publication number
AU2002332391A1
AU2002332391A1 AU2002332391A AU2002332391A AU2002332391A1 AU 2002332391 A1 AU2002332391 A1 AU 2002332391A1 AU 2002332391 A AU2002332391 A AU 2002332391A AU 2002332391 A AU2002332391 A AU 2002332391A AU 2002332391 A1 AU2002332391 A1 AU 2002332391A1
Authority
AU
Australia
Prior art keywords
secreted proteins
human secreted
human
proteins
secreted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002332391A
Inventor
Craig A. Rosen
Steven M. Ruben
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Human Genome Sciences Inc
Original Assignee
Human Genome Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Human Genome Sciences Inc filed Critical Human Genome Sciences Inc
Publication of AU2002332391A1 publication Critical patent/AU2002332391A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Obesity (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AU2002332391A 2001-03-21 2002-03-19 Human secreted proteins Abandoned AU2002332391A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US27734001P 2001-03-21 2001-03-21
US60/277,340 2001-03-21
US30617101P 2001-07-19 2001-07-19
US60/306,171 2001-07-19
US33128701P 2001-11-13 2001-11-13
US60/331,287 2001-11-13
PCT/US2002/008123 WO2002102993A2 (en) 2001-03-21 2002-03-19 Human secreted proteins

Publications (1)

Publication Number Publication Date
AU2002332391A1 true AU2002332391A1 (en) 2003-01-02

Family

ID=27402891

Family Applications (6)

Application Number Title Priority Date Filing Date
AU2002363296A Abandoned AU2002363296A1 (en) 2001-03-21 2002-03-19 Human secreted proteins
AU2002324424A Abandoned AU2002324424A1 (en) 2001-03-21 2002-03-19 Human secreted proteins
AU2002332391A Abandoned AU2002332391A1 (en) 2001-03-21 2002-03-19 Human secreted proteins
AU2002326293A Abandoned AU2002326293A1 (en) 2001-03-21 2002-03-19 Human secreted proteins
AU2002354719A Abandoned AU2002354719A1 (en) 2001-03-21 2002-03-19 Human secreted proteins
AU2002320013A Abandoned AU2002320013A1 (en) 2001-03-21 2002-03-19 Human secreted proteins

Family Applications Before (2)

Application Number Title Priority Date Filing Date
AU2002363296A Abandoned AU2002363296A1 (en) 2001-03-21 2002-03-19 Human secreted proteins
AU2002324424A Abandoned AU2002324424A1 (en) 2001-03-21 2002-03-19 Human secreted proteins

Family Applications After (3)

Application Number Title Priority Date Filing Date
AU2002326293A Abandoned AU2002326293A1 (en) 2001-03-21 2002-03-19 Human secreted proteins
AU2002354719A Abandoned AU2002354719A1 (en) 2001-03-21 2002-03-19 Human secreted proteins
AU2002320013A Abandoned AU2002320013A1 (en) 2001-03-21 2002-03-19 Human secreted proteins

Country Status (4)

Country Link
EP (7) EP1381622A2 (en)
AU (6) AU2002363296A1 (en)
CA (7) CA2441840A1 (en)
WO (7) WO2002090526A2 (en)

Families Citing this family (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7196164B2 (en) 1997-07-08 2007-03-27 Human Genome Sciences, Inc. Secreted protein HHTLF25
JP2002513295A (en) 1997-07-08 2002-05-08 ヒューマン・ジェノム・サイエンシズ・インコーポレイテッド 123 human secreted proteins
PT1086223E (en) 1998-06-01 2009-11-03 Agensys Inc Novel serpentine transmembrane antigens expressed in human cancers and uses thereof
US20030149531A1 (en) 2000-12-06 2003-08-07 Hubert Rene S. Serpentine transmembrane antigens expressed in human cancers and uses thereof
US20040141975A1 (en) 1998-06-01 2004-07-22 Raitano Arthur B. Nucleic acid and corresponding protein entitled 98P4B6 useful in treatment and detection of cancer
US6833438B1 (en) 1999-06-01 2004-12-21 Agensys, Inc. Serpentine transmembrane antigens expressed in human cancers and uses thereof
US20060052321A1 (en) 2002-04-05 2006-03-09 Raitano Arthur B Nucleic acid and corresponding protein entitled 98P4B6 useful in treatment and detection of cancer
EP1141027A1 (en) 1999-01-15 2001-10-10 Biogen, Inc. Antagonists of tweak and of tweak receptor and their use to treat immunological disorders
US7291719B2 (en) 2000-07-25 2007-11-06 Genentech, Inc. PRO4332 antibodies
EP1666490A3 (en) * 2000-07-25 2006-11-02 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
EP1364021A2 (en) 2000-10-31 2003-11-26 Diadexus, Inc. Compositions and methods relating to colon specific genes and proteins
US20020111302A1 (en) * 2000-11-30 2002-08-15 Y. Tom Tang Novel nucleic acids and polypeptides
EP1573024A4 (en) * 2001-04-10 2007-08-29 Agensys Inc Nuleic acids and corresponding proteins useful in the detection and treatment of various cancers
US20030119112A1 (en) 2001-06-20 2003-06-26 Genentech, Inc. Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
EP1429793B1 (en) 2001-09-06 2015-02-25 Agensys, Inc. Nucleic acid and corresponding protein entitled steap-1 useful in treatment and detection of cancer
US7494646B2 (en) 2001-09-06 2009-02-24 Agensys, Inc. Antibodies and molecules derived therefrom that bind to STEAP-1 proteins
JPWO2003033727A1 (en) 2001-10-12 2005-02-03 山之内製薬株式会社 Cell death inhibitor screening method
SI1997512T1 (en) 2002-04-09 2014-03-31 Biogen Idec Ma Inc. Methods for treating TWEAK-related conditions
AU2003900747A0 (en) * 2003-02-18 2003-03-06 Garvan Institute Of Medical Research Diagnosis and treatment of pancreatic cancer
US7709610B2 (en) 2003-05-08 2010-05-04 Facet Biotech Corporation Therapeutic use of anti-CS1 antibodies
US20050025763A1 (en) 2003-05-08 2005-02-03 Protein Design Laboratories, Inc. Therapeutic use of anti-CS1 antibodies
WO2005019258A2 (en) * 2003-08-11 2005-03-03 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
EP2380985B1 (en) 2003-09-23 2014-01-01 University of North Carolina at Chapel Hill Cells expressing vitamin K epoxide reductase and use thereof
EP2272951B1 (en) * 2003-10-14 2014-07-23 Baxter International Inc. Vitamin k epoxide recycling polypeptide vkorc1, a therapeutic target of coumarin and their derivatives
US20070269421A1 (en) * 2004-02-03 2007-11-22 Bayer Healthcare Ag Diagnostics and Therapeutics for Diseases Associated with Plasma Glutamate Carboxypeptidase (Pgcp)
US20050186577A1 (en) 2004-02-20 2005-08-25 Yixin Wang Breast cancer prognostics
US8008442B2 (en) 2004-04-22 2011-08-30 Agensys, Inc. Antibodies and molecules derived therefrom that bind to STEAP-1 proteins
ES2543207T3 (en) 2004-09-01 2015-08-17 Dynavax Technologies Corporation Methods and compositions for the inhibition of innate immune responses and autoimmunity
EP1799849A4 (en) * 2004-09-07 2008-07-09 Telethon Inst For Child Health Agents for treatment or prevention of an allergic disorder
WO2006026808A1 (en) * 2004-09-07 2006-03-16 Telethon Institute For Child Health Research Method of diagnosing and/or predicting the development of an allergic disorder
DK2332408T3 (en) 2005-02-17 2013-12-02 Biogen Idec Inc Treatment of neurological diseases
MX349285B (en) 2005-02-28 2017-07-20 Baxalta Inc Recombinant co-expression of vitamin k epoxide reductase subunit 1 to improve vitamin k dependent protein expression.
JP2008532544A (en) 2005-03-15 2008-08-21 ユニヴァーシティ・オヴ・ノース・キャロライナ・アト・チャペル・ヒル Methods and compositions for producing active vitamin K-dependent proteins
WO2006122187A2 (en) 2005-05-10 2006-11-16 Biogen Idec Ma Inc. Treating and evaluating inflammatory disorders
WO2006138219A2 (en) 2005-06-13 2006-12-28 Biogen Idec Ma Inc. Methods of diagnosis / prognosis of inflammatory conditions
GB2445882B (en) * 2005-09-01 2011-02-23 Florey Howard Inst Prophylactic and therapeutic agents and compositions and uses therefor and methods for determining the presence or severity of neuronal damage
GB0521488D0 (en) * 2005-10-21 2005-11-30 Ares Trading Sa Integral membrane protein
US7572618B2 (en) 2006-06-30 2009-08-11 Bristol-Myers Squibb Company Polynucleotides encoding novel PCSK9 variants
PL2845866T3 (en) 2006-10-27 2017-10-31 Genentech Inc Antibodies and immunoconjugates and uses therefor
CN101636179B (en) 2006-11-07 2012-10-10 默沙东公司 Antagonists of pcsk9
US8093222B2 (en) 2006-11-27 2012-01-10 Isis Pharmaceuticals, Inc. Methods for treating hypercholesterolemia
WO2008118386A2 (en) * 2007-03-27 2008-10-02 Merck & Co., Inc. Method for detecting autoprocessed, secreted pcsk9
JOP20080381B1 (en) 2007-08-23 2023-03-28 Amgen Inc Antigen Binding Proteins to Proprotein Convertase subtillisin Kexin type 9 (pcsk9)
WO2009055076A2 (en) 2007-10-26 2009-04-30 Dynavax Technologies Corporation Methods and compositions for inhibition of immune responses and autoimmunity
CN101932728B (en) * 2007-11-30 2013-06-19 西门子医疗保健诊断公司 Adiponectin receptor fragments and methods of use
AR070316A1 (en) 2008-02-07 2010-03-31 Merck & Co Inc PCSK9 ANTAGONISTS (SUBTILISINE-KEXINA TYPE 9 PROPROTEIN)
AR070315A1 (en) 2008-02-07 2010-03-31 Merck & Co Inc ANTIBODIES 1B20 ANTAGONISTS OF PCSK9
US8748115B2 (en) 2008-12-12 2014-06-10 Merck Sharp & Dohme Corp. PCSK9 immunoassay
US8877900B2 (en) 2009-10-30 2014-11-04 Merck Sharp & Dohme Corp. AX132 PCSK9 antagonists
CA2777698A1 (en) 2009-10-30 2011-05-05 Merck Sharp & Dohme Corp. Ax1 and ax189 pcsk9 antagonists and variants
AU2011268211B2 (en) 2010-06-16 2015-07-16 Dynavax Technologies Corporation Methods of treatment using TLR7 and/or TLR9 inhibitors
JP6012605B2 (en) 2010-09-22 2016-10-25 アリオス バイオファーマ インク． Substituted nucleotide analogs
US9631002B2 (en) 2010-12-21 2017-04-25 The University Of North Carolina At Chapel Hill Methods and compositions for producing active vitamin K-dependent proteins
US8980865B2 (en) 2011-12-22 2015-03-17 Alios Biopharma, Inc. Substituted nucleotide analogs
US8916538B2 (en) 2012-03-21 2014-12-23 Vertex Pharmaceuticals Incorporated Solid forms of a thiophosphoramidate nucleotide prodrug
EP2827876A4 (en) 2012-03-22 2015-10-28 Alios Biopharma Inc Pharmaceutical combinations comprising a thionucleotide analog
US9023359B1 (en) 2014-07-15 2015-05-05 Kymab Limited Targeting rare human PCSK9 variants for cholesterol treatment
US8945560B1 (en) 2014-07-15 2015-02-03 Kymab Limited Method of treating rheumatoid arthritis using antibody to IL6R
US8992927B1 (en) 2014-07-15 2015-03-31 Kymab Limited Targeting human NAV1.7 variants for treatment of pain
US9914769B2 (en) 2014-07-15 2018-03-13 Kymab Limited Precision medicine for cholesterol treatment
US9067998B1 (en) 2014-07-15 2015-06-30 Kymab Limited Targeting PD-1 variants for treatment of cancer
US9045545B1 (en) 2014-07-15 2015-06-02 Kymab Limited Precision medicine by targeting PD-L1 variants for treatment of cancer
US9017678B1 (en) 2014-07-15 2015-04-28 Kymab Limited Method of treating rheumatoid arthritis using antibody to IL6R
US9045548B1 (en) 2014-07-15 2015-06-02 Kymab Limited Precision Medicine by targeting rare human PCSK9 variants for cholesterol treatment
US8986691B1 (en) 2014-07-15 2015-03-24 Kymab Limited Method of treating atopic dermatitis or asthma using antibody to IL4RA
US9034332B1 (en) 2014-07-15 2015-05-19 Kymab Limited Precision medicine by targeting rare human PCSK9 variants for cholesterol treatment
US8986694B1 (en) 2014-07-15 2015-03-24 Kymab Limited Targeting human nav1.7 variants for treatment of pain
US8980273B1 (en) 2014-07-15 2015-03-17 Kymab Limited Method of treating atopic dermatitis or asthma using antibody to IL4RA
US9051378B1 (en) 2014-07-15 2015-06-09 Kymab Limited Targeting rare human PCSK9 variants for cholesterol treatment
US8883157B1 (en) 2013-12-17 2014-11-11 Kymab Limited Targeting rare human PCSK9 variants for cholesterol treatment
US9682218B2 (en) 2013-12-23 2017-06-20 Carefusion 2200, Inc. Pleurodesis device and method
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
US9139648B1 (en) 2014-07-15 2015-09-22 Kymab Limited Precision medicine by targeting human NAV1.9 variants for treatment of pain
US9150660B1 (en) 2014-07-15 2015-10-06 Kymab Limited Precision Medicine by targeting human NAV1.8 variants for treatment of pain
EP3534947A1 (en) 2016-11-03 2019-09-11 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses & methods
CA3048479A1 (en) 2016-12-23 2018-06-28 President And Fellows Of Harvard College Gene editing of pcsk9
ES2955852T3 (en) 2017-04-03 2023-12-07 Hoffmann La Roche STEAP-1 binding antibodies
CN110709174A (en) 2017-06-22 2020-01-17 宝洁公司 Film comprising a water-soluble layer and a vapor-deposited organic coating
WO2018237213A1 (en) 2017-06-22 2018-12-27 The Procter & Gamble Company Films including a water-soluble layer and a vapor-deposited inorganic coating
GB2623891B (en) 2020-04-09 2024-10-23 Verve Therapeutics Inc Base editing of ANGPTL3 and methods of using same for treatment of disease

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100236393B1 (en) * 1996-02-02 1999-12-15 나까니시 히로유끼 A pharmaceutical preparation containing a human growth hormone
WO2002026931A2 (en) * 2000-09-25 2002-04-04 Human Genome Sciences, Inc. 71 human secreted proteins
US5858716A (en) * 1997-05-30 1999-01-12 Smithkline Beecham Corporation H2CAA71 polynucleotides
CA2333917A1 (en) * 1998-07-15 2000-01-27 Human Genome Sciences, Inc. 71 human secreted proteins

Also Published As

Publication number Publication date
WO2003038063A2 (en) 2003-05-08
WO2003038063A3 (en) 2003-12-11
EP1390390A2 (en) 2004-02-25
EP1379132A2 (en) 2004-01-14
CA2441397A1 (en) 2002-10-03
CA2441832A1 (en) 2002-12-27
AU2002320013A1 (en) 2002-11-18
AU2002324424A1 (en) 2002-12-03
WO2003004622A3 (en) 2004-02-19
WO2003004622A2 (en) 2003-01-16
WO2002102993A3 (en) 2004-03-25
WO2002095010A2 (en) 2002-11-28
EP1390390A4 (en) 2009-07-08
CA2441416A1 (en) 2003-01-16
AU2002363296A1 (en) 2003-05-12
EP1404702A2 (en) 2004-04-07
EP1404702A4 (en) 2009-07-08
CA2441840A1 (en) 2002-11-28
EP1379132A4 (en) 2009-07-01
AU2002354719A1 (en) 2003-01-21
CA2441417A1 (en) 2002-11-14
WO2002102994A3 (en) 2003-07-24
AU2002326293A1 (en) 2003-01-02
EP1381622A2 (en) 2004-01-21
EP1423134A2 (en) 2004-06-02
EP1414845A4 (en) 2009-07-08
WO2002102993A2 (en) 2002-12-27
EP1414845A2 (en) 2004-05-06
WO2002090526A3 (en) 2003-10-30
WO2002095010A3 (en) 2004-02-12
EP1379264A4 (en) 2009-07-08
WO2002090526A2 (en) 2002-11-14
WO2002102994A2 (en) 2002-12-27
EP1379264A1 (en) 2004-01-14
WO2002076488A1 (en) 2002-10-03
CA2441755A1 (en) 2003-05-08
CA2441702A1 (en) 2002-12-27

Similar Documents

Publication Publication Date Title
AU2002324424A1 (en) Human secreted proteins
AU2002341538A1 (en) Human secreted proteins
AU2002361452A1 (en) Secreted proteins
AU2002232596A1 (en) Secreted human proteins
AU2002353227A1 (en) Secreted proteins
AU2002342010A1 (en) Secreted proteins
AU2002354803A1 (en) Secreted proteins
AU2003301843A1 (en) 157 human secreted proteins
AU2002255733A1 (en) Secreted proteins
AU2002252700A1 (en) Secreted proteins
AU2001294719A1 (en) Secreted human proteins
AU2002327533A1 (en) Secreted proteins
AU2002258657A1 (en) Secreted proteins
AU2002365153A1 (en) 41 human secreted proteins
AU2002327176A1 (en) 20 human secreted proteins
AU2002246998A1 (en) 50 human secreted proteins
AU2002348034A1 (en) 16 human secreted proteins
AU2002254275A1 (en) Human secreted proteins
AU2003211137A1 (en) 20 human secreted proteins
AU2002257630A1 (en) Human mrp5-like protein
AU2002253985A1 (en) 83 human secreted proteins
AU2002247189A1 (en) 70 human secreted proteins
AU2002332483A1 (en) 13 human secreted proteins
AU2002303843A1 (en) Secreted proteins
AU2002352912A1 (en) Secreted proteins

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase